BRAZZAVILLE, Congo (Republic of the), February 4, 2021/APO Group/ â
COVAX has notified countries in Africa of the estimated dose allocation for the first phase of COVID-19 vaccine delivery. The global initiative led by the World Health Organization (WHO), Gavi the Vaccine Alliance and The Coalition for Epidemic Preparedness Innovations (CEPI) aims to start shipping nearly 90 million COVID-19 vaccine doses to the continent in February, in what will be Africaâs largest ever mass vaccination campaign.
The roll-out of the AstraZeneca/Oxford AZD1222 vaccine is subject to the vaccine being listed for emergency use by WHO. The organization is currently reviewing the vaccine and the outcome of the review is expected soon.
Coronavirus - Africa: COVAX expects to start sending millions of COVID-19 vaccines to Africa in February
The roll-out of the AstraZeneca/Oxford AZD1222 vaccine is subject to the vaccine being listed for emergency use by WHO
BRAZZAVILLE, Congo (Republic of the), February 4, 2021/APO Group/
COVAX has notified countries in Africa of the estimated dose allocation for the first phase of COVID-19 vaccine delivery. The global initiative led by the World Health Organization (WHO), Gavi the Vaccine Alliance and The Coalition for Epidemic Preparedness Innovations (CEPI) aims to start shipping nearly 90 million COVID-19 vaccine doses to the continent in February, in what will be Africa’s largest ever mass vaccination campaign.
COVAX expects to start sending millions of COVID-19 vaccines to Africa in February
Format
Brazzaville – COVAX has notified countries in Africa of the estimated dose allocation for the first phase of COVID-19 vaccine delivery. The global initiative led by the World Health Organization (WHO), Gavi the Vaccine Alliance and The Coalition for Epidemic Preparedness Innovations (CEPI) aims to start shipping nearly 90 million COVID-19 vaccine doses to the continent in February, in what will be Africa’s largest ever mass vaccination campaign.
The roll-out of the AstraZeneca/Oxford AZD1222 vaccine is subject to the vaccine being listed for emergency use by WHO. The organization is currently reviewing the vaccine and the outcome of the review is expected soon.
The roll-out of the AstraZeneca/Oxford AZD1222 vaccine is subject to the vaccine being listed for emergency use by WHO. The organization is currently reviewing the vaccine and the outcome of the review is expected soon.
“Africa has watched other regions start COVID-19 vaccination campaigns from the side-lines for too long. This planned roll-out is a critical first step to ensuring the continent gets equitable access to vaccines,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “We know no one will be safe until everyone is safe.”
COVAX notified countries through letters which were sent on 30 January 2021. Amid surging demand for COVID-19 vaccines, the final shipments will be based on production capacities of vaccine manufacturers and the readiness of countries. Recipient countries are required to submit finalized national deployment and vaccination plans to receive vaccines from the COVAX facility.
COVID-19 cases in the African region have risen steadily over the past two months, underscoring the need for reinforced public health measures to avert a surge in infections, particularly as people gather or travel for end-of-year celebrations.
Since mid-October, an average of 46 000 cases per week have been recorded in the 47 countries in the World Health Organization (WHO) African region compared with about 29 000 cases per week between early September and early October. Ten countries in the region have reported the highest number of cases, accounting for 88% of new cases in the past month. However, seven countries have recorded a steady decline in cases over the past four weeks.